Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Mirikizumab Autoinjector vs Pre-filled Syringe in Healthy Subjects
NCT03662100Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2018
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mirikizumab in ulcerative colitis (UC) and Crohn's disease (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of LY3074828 at Day 85, Area Under the Concentration Versus Time Curve at Day 85 and 1 more. Started Sep 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03662100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662100.